The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

The FDA recently announced that the Psoriasis drug, Raptiva, has been linked to three, and possibly a fourth, cases of Progressive Multifocal Leukoencephalopathy (PML). PML is a brain infection that causes serious neurological problems. Most people who develop PML die within 6 months. Unfortunately, all three of the confirmed cases of PML linked to Rapitva have resulted in death.

Raptiva is one of the most commonly used drugs for the treatment of Psoriasis. Psoriasis is an immune system disorder that leads to inflammation of the skin. The inflammation cuases patches of scaly, red skin, and the skin can itch or burn. Raptiva is a once-a-week injection.

Signs and symptoms of PML include: confusion, dizziness, loss of balance or coordination, visual impairment, seizures, and difficulting talking or walking.

Patients using Raptiva injections for the treatment of Psoriasis should be on the lookout for the development of any neurological problems. Patients should consult their doctors immediately for any problems that develop.

Comments are closed.

Of Interest